Cargando…

Efficacy of Vildagliptin Added to Continuous Subcutaneous Insulin Infusion (CSII) in Hospitalized Patients with Type 2 Diabetes

INTRODUCTION: The aim of this study was to compare the efficacy of vildagliptin as add-on therapy to short-term continuous subcutaneous insulin infusion (CSII) with CSII monotherapy in hospitalized patients with type 2 diabetes mellitus (T2DM). METHODS: A total of 200 hospitalized patients with inad...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lyu, Fu-ping, Huang, Bing-kun, Su, Wei-juan, Yan, Fang-fang, Zeng, Jin-yang, Chen, Zheng, Zhang, Yu-xian, Wang, Shun-hua, Huang, Yin-xiang, Zhang, Mu-lin, Shi, Xiu-lin, Lin, Ming-zhu, Li, Xue-jun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7048888/ https://www.ncbi.nlm.nih.gov/pubmed/32020552 http://dx.doi.org/10.1007/s13300-020-00758-5

Ejemplares similares

Management of glycemic variation in diabetic patients receiving parenteral nutrition by continuous subcutaneous insulin infusion (CSII) therapy
por: Li, Feng-fei, et al.
Publicado: (2018)

A Review of Insulin-Dosing Formulas for Continuous Subcutaneous Insulin Infusion (CSII) for Adults with Type 1 Diabetes
por: King, Allen B., et al.
Publicado: (2016)

Economic evaluation of continuous subcutaneous insulin infusion for children with diabetes - a pilot study: CSII application for children – economic evaluation
por: Petkova, Elina, et al.
Publicado: (2013)

Development and validation of an instrument (CSII – Brazil) to assess users’ conceptual and procedural knowledge of continuous subcutaneous infusion systems
por: Amaral, Camilla Magalhães de Oliveira, et al.
Publicado: (2020)

Long-Term Effects of Initiating Continuous Subcutaneous Insulin Infusion (CSII) and Continuous Glucose Monitoring (CGM) in People with Type 1 Diabetes and Unsatisfactory Diabetes Control
por: Senn, Jon-Duri, et al.
Publicado: (2019)

Continuous Subcutaneous Insulin Infusion (CSII) Combined with Oral Glucose-Lowering Drugs in Type 2 Diabetes: A Systematic Review and Network Meta-Analysis of Randomized, Controlled Trials
por: Li, Hui, et al.
Publicado: (2022)

HbA1c variability in adults with type 1 diabetes on continuous subcutaneous insulin infusion (CSII) therapy compared to multiple daily injection (MDI) treatment
por: Scott, Emma S, et al.
Publicado: (2019)

Experiences and decision making during paediatric transitions to continuous sub-cutaneous insulin infusion (CSII): A mixed method study
por: Altmann, Erika, et al.
Publicado: (2018)

Continuous subcutaneous insulin infusion: practical issues
por: Saboo, Banshi D., et al.
Publicado: (2012)

Effectiveness of Multiple Daily Injections or Continuous Subcutaneous Insulin Infusion for Children with Type 1 Diabetes Mellitus in Clinical Practice
por: Gong, Chun-xiu, et al.
Publicado: (2014)

Risk Factors for Glycemic Control in Hospitalized Patients with Type 2 Diabetes Receiving Continuous Subcutaneous Insulin Infusion Therapy
por: Wang, Shun-hua, et al.
Publicado: (2022)

Faster Insulin Aspart for Continuous Subcutaneous Insulin Infusion: Is It Worth It?
por: Rosinha, Patrícia, et al.
Publicado: (2022)

A Continuous Subcutaneous Insulin Infusion Needle Break
por: George, Minu M., et al.
Publicado: (2015)

Glucose Variability and β- Cell Response by GLP-1 Analogue added-on CSII for Patients with Poorly Controlled Type 2 Diabetes
por: Lin, Chia-Hung, et al.
Publicado: (2015)

Psychopathology and Continuous Subcutaneous Insulin Infusion in Type 1 Diabetes
por: Rotella, Francesco, et al.
Publicado: (2013)

Metformin add-on continuous subcutaneous insulin infusion on precise insulin doses in patients with type 2 diabetes
por: Li, Feng-fei, et al.
Publicado: (2018)

A Randomized Trial of Insulin Glargine plus Oral Hypoglycemic Agents versus Continuous Subcutaneous Insulin Infusion to Treat Newly Diagnosed Type 2 Diabetes
por: Lin, Shuo, et al.
Publicado: (2018)

Evaluation of the Accuracy of Current Tubeless Pumps for Continuous Subcutaneous Insulin Infusion
por: Ziegler, Ralph, et al.
Publicado: (2021)

Polymorphic Basal Rates of Continuous Subcutaneous Insulin Infusion among Taiwanese Children with Type 1 Diabetes
por: Lin, Chia-Hung, et al.
Publicado: (2015)

Continuous subcutaneous insulin infusion is associated with a reduced rate of microvascular complications
por: Zabeen, Bedowra, et al.
Publicado: (2015)

Continuous subcutaneous insulin infusion in diabetes: patient populations, safety, efficacy, and pharmacoeconomics
por: Pozzilli, Paolo, et al.
Publicado: (2015)

Continuous subcutaneous insulin infusion and flash glucose monitoring in diabetic hemiballism-hemichorea
por: Qiang, Wei, et al.
Publicado: (2020)

Continuous Subcutaneous Insulin Infusion Characteristics in Type 1 Diabetes Children and Adolescents in Qatar
por: Petrovski, Goran, et al.
Publicado: (2018)

Insulin Pump for Type 2 Diabetes: Use and misuse of continuous subcutaneous insulin infusion in type 2 diabetes
por: Reznik, Yves, et al.
Publicado: (2013)

Detailed Analysis of Insulin Absorption Variability and the Tissue Response to Continuous Subcutaneous Insulin Infusion Catheter Implantation in Swine
por: Hauzenberger, Jasmin R., et al.
Publicado: (2017)

Continuous subcutaneous insulin infusion therapy is associated with reduced retinopathy progression compared with multiple daily injections of insulin
por: Reid, Laura J., et al.
Publicado: (2021)

Postnatal growth of infants with neonatal diabetes: Insulin pump (CSII) versus Multiple Daily Injection (MDI) therapy
por: Alyafie, Fawzia, et al.
Publicado: (2019)

Outcomes for continuous subcutaneous insulin infusion users in young adults from lower socioeconomic backgrounds
por: McKee, Alexis M., et al.
Publicado: (2021)

Comparing the effectiveness of continuous subcutaneous insulin infusion with multiple daily insulin injection for patients with type 1 diabetes mellitus evaluated by retrospective continuous glucose monitoring: A real-world data analysis
por: Keyu, Guo, et al.
Publicado: (2022)

Diurnal variation of carbohydrate insulin ratio in adult type 1 diabetic patients treated with continuous subcutaneous insulin infusion
por: Nakamura, Tomoaki, et al.
Publicado: (2014)

Lost in Translation: A Disconnect Between the Science and Medicare Coverage Criteria for Continuous Subcutaneous Insulin Infusion
por: Aleppo, Grazia, et al.
Publicado: (2021)

Continuous Subcutaneous Insulin Infusion Therapy Resulting in Improved Glycemic Control in Patient With Low Health Literacy
por: Mandal, Shobha, et al.
Publicado: (2021)

Intradermal insulin infusion achieves faster insulin action than subcutaneous infusion for 3-day wear
por: Rini, Christopher James, et al.
Publicado: (2015)

CSII treatment as an option in high-risk pregnant patients with type 1 diabetes
por: Breder, Íkaro Soares Santos, et al.
Publicado: (2015)

Short-Term Effect of Continuous Subcutaneous Insulin Infusion and Multiple Daily Injection in Perioperative Patients with Type 2 Diabetes Mellitus
por: Song, Wei, et al.
Publicado: (2023)

Continuous Intravenous versus Subcutaneous Administration of Insulin for Glycemic Variability in Acute Ischemic Stroke
por: Du, Lin-Zhe, et al.
Publicado: (2022)

Dental caries and bacterial load in saliva and dental biofilm of type 1 diabetics on continuous subcutaneous insulin infusion
por: COELHO, Ana, et al.
Publicado: (2018)

Continuous Subcutaneous Insulin Infusion in Children: A Pilot Study Validating a Protocol to Avoid Hypoglycemia at Initiation
por: Manousaki, Despoina, et al.
Publicado: (2017)

The Lived Experience of Continuous Subcutaneous Insulin Infusion in Adults With Type 1 Diabetes Mellitus: A Phenomenological Inquiry
por: Callahan Fagan, V. Renee, et al.
Publicado: (2021)

Continuous subcutaneous insulin infusion alters microRNA expression and glycaemic variability in children with type 1 diabetes
por: Scott, Emma S., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_73jrpjkkorrd8dp7ggebe388kt